A Trojan horse approach for enhancing the cellular uptake of a ruthenium nitrosyl complex

Abstract

Ruthenium nitrosyl (RuNO) complexes continue to attract significant research interest due to several appealing features that make these photoactivatable nitric oxide (NO·) donors attractive for applications in photoactivated chemotherapy. Interesting...

The phototoxic effect of a gold-antibody-based nanocarrier of phthalocyanine on melanoma monolayers and tumour spheroids

“…The synthesised molecule exhibited a strong cellular uptake towards dermal fibroblasts with a remarkable 10-fold uptake when compared to free RuNO, thus suggesting the potential drug-targeting abilities of this biomimetic steroidal conjugate. 21 Studies state that Melanoma Inhibitory Activity (MIA) is an antigen closely associated with melanoma surface proteins, which makes it more realistic for targeting in order to enhance the bioavailability of anticancer agents in melanoma cells. 4,22 In light of this, the immobilisation of melanoma tumour-targeting entities, such as anti-MIA antibodies (Ab), onto the surface of ZnPcS nanocarrier platforms would ultimately improve the safety profile and the target-selectivity of these PSs, leading to better PDT therapeutic outcomes.…”